Zai Lab
Zai Lab Limited, commonly referred to as Zai Lab, is a prominent biopharmaceutical company headquartered in China. Founded in 2014, the company has rapidly established itself as a leader in the development of innovative therapies, focusing primarily on oncology, autoimmune diseases, and infectious diseases. With a strong operational presence in both China and the United States, Zai Lab is committed to addressing unmet medical needs through its robust pipeline of novel drug candidates. The company’s core offerings include a range of proprietary and partnered products, distinguished by their unique mechanisms of action and potential to improve patient outcomes. Zai Lab has achieved significant milestones, including successful collaborations with global pharmaceutical leaders and the launch of several key therapies in the Chinese market. Recognised for its commitment to innovation, Zai Lab continues to strengthen its position in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Zai Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zai Lab's score of 37 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zai Lab's reported carbon emissions
In 2023, Zai Lab, headquartered in China, reported total carbon emissions of approximately 70,321,000 kg CO2e. This figure includes 65,642,000 kg CO2e from Scope 1 emissions, 4,664,000 kg CO2e from Scope 2 emissions, and 70,321,000 kg CO2e from Scope 3 emissions. The company has shown a commitment to reducing its carbon footprint, although it has not set specific reduction targets or a net-zero commitment as of now. In 2022, Zai Lab's total emissions were about 73,481,000 kg CO2e, with Scope 1 emissions at 70,463,000 kg CO2e and Scope 2 emissions at 3,954,000 kg CO2e. The increase in emissions from 2022 to 2023 indicates a need for enhanced sustainability measures. Zai Lab is actively engaged in the pharmaceutical, biotechnology, and life sciences sector, which is increasingly under pressure to address climate change. The company is currently committed to near-term targets but has not yet established long-term goals. As the industry evolves, Zai Lab's future commitments will be crucial in aligning with global climate initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 28,400 | 00,000,000 | 00,000,000 |
| Scope 2 | 3,536,600 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zai Lab is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
